Valuation: Zeo ScientifiX, Inc.

Market Cap 12.31M 10.55M 9.87M 9.03M 16.95M 1.18B 17.18M 117M 45.47M 592M 46.23M 45.23M 1.96B P/E 2024
-2.29x
P/E 2025 -2.17x
Enterprise Value 12.44M 10.66M 9.97M 9.13M 17.14M 1.19B 17.36M 118M 45.96M 598M 46.73M 45.71M 1.98B EV / Sales 2024
2.43x
EV / Sales 2025 2.45x
Free-Float
50.57%
Yield 2024 *
-
Yield 2025 -
16/06 Zeo ScientifiX, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2026 CI
09/06 Zeo Scientifix, Inc. Announces Management Changes CI
09/04 Zeo Scientifix Inc - enters MoU with Regen Therapy for exclusive scientific and biologics collaboration - SEC filing RE
09/04 Regen Therapy Partners with Stealth Health to Bring Specialized Telemedicine Services and Longevity Programs to 3,000 Clinics-Powered by an Exclusive Scientific and Biologics Strategic Collaboration with ZEO Scientifix CI
28/03 Zeo Scientifix, Inc. Announces Termination of Dr. John D. Kisiday as Chief Science Officer Effective March 23, 2026 CI
18/03 Zeo ScientifiX, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2026 CI
30/01 Zeo ScientifiX, Inc. Reports Earnings Results for the Full Year Ended October 31, 2025 CI
29/01 Zeo ScientifiX, Inc. Auditor Raises 'Going Concern' Doubt CI
28/01 Zeo Scientifix, Inc. Appoints John D. Kisiday as Chief Science Officer, Effective January 23, 2026 CI
08/01 Cytora Therapeutics, Made Scientific, and Zeo Scientifix Announce Partnership to Manufacture and Commercialize Cytora's Allogeneic Stem Cell Therapy in the United States CI
07/01 Cytora Therapeutics partners with Made Scientific, and Zeo Scientifix to manufacture allogeneic stem cell therapy RE
05/01 Zeo ScientifiX, Inc. Appoints Ian T. Bothwell as Full-Time Chief Executive Officer, Effective December 24, 2025 CI
04/12 Zeo Scientifix, Inc. Terminates Ron Borsheim as Chief Sales Officer Aesthetics, Effective November 30, 2025 CI
1 day-5.79%
1 week+27.86%
Current month+53.78%
1 month+1.13%
3 months-9.60%
6 months-19.73%
Current year-33.95%
1 week 1.33
Extreme 1.334
1.88
1 month 0.97
Extreme 0.97
1.88
Current year 0.97
Extreme 0.97
2.98
1 year 0.97
Extreme 0.97
2.99
3 years 0.8
Extreme 0.8
4.73
5 years 0.8
Extreme 0.8
22
10 years 0.7
Extreme 0.7
125.98
Manager TitleAgeSince
Chief Executive Officer 65 01/06/2024
Chief Tech/Sci/R&D Officer - 01/01/2020
Compliance Officer - 01/04/2025
Director TitleAgeSince
Director/Board Member 65 11/09/2019
Director/Board Member 78 23/09/2022
Director/Board Member 64 19/08/2022
Date Insider Type Main position Quantity % Market Cap.
10/6/26 Free

Chief Executive Officer

1,250,000 16.0721%
23/1/26 Other

Chief Technology Officer

50,000 0.7632%
14/1/26
Greyt Ventures LLC
FreeCompany 175,000 2.6713%
Change 5-day change 1-year change 3-year change Capi.($)
-5.79%+27.86%+6.55%-47.66% 12.31M
+0.36%+0.57%+27.38%+104.28% 100B
-0.55%-2.78%+56.88%+165.88% 53.38B
-0.69%-2.37%0.00%+266.88% 23.91B
-2.82%-2.41%-15.28%-13.14% 8.09B
-6.08%-5.45%-38.42%-23.27% 7.33B
-1.92%-2.80%-17.98%-25.60% 6.63B
+0.71%-4.27%+5.79%+20.48% 6.34B
+0.18%+1.05%-3.20%+18.38% 5.09B
-0.55%+2.98%+9.16%+18.72% 3.76B
Average -1.72%-1.20%+3.09%+48.49% 21.47B
Weighted average by Cap. -0.40%-1.69%+24.73%+118.90%

Financials

2024 2025
Net sales 4.62M 3.96M 3.7M 3.39M 6.36M 442M 6.45M 43.75M 17.06M 222M 17.35M 16.97M 734M 5.2M 4.45M 4.17M 3.81M 7.16M 497M 7.25M 49.23M 19.2M 250M 19.52M 19.1M 827M
Net income -4.7M -4.03M -3.77M -3.45M -6.48M -450M -6.56M -44.55M -17.37M -226M -17.67M -17.28M -748M -5.52M -4.73M -4.43M -4.05M -7.6M -528M -7.7M -52.28M -20.39M -265M -20.73M -20.28M -878M
Net Debt 36K 30.84K 28.85K 26.41K 49.57K 3.44M 50.22K 341K 133K 1.73M 135K 132K 5.72M 132K 113K 106K 96.85K 182K 12.63M 184K 1.25M 487K 6.34M 496K 485K 20.98M
Logo Zeo ScientifiX, Inc.
Zeo ScientifiX, Inc. is a clinical-stage biopharmaceutical company. The Company is primarily focused on developing innovative biological therapeutics for regenerative medicine and the treatment of degenerative diseases. Its proprietary products, including Zofin, which are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, proteins and cell secreted nanoparticles, and Patient Pure X (PPX), an autologous biologic containing a nanoparticle fraction that is precipitated from a patient’s own peripheral blood (RAAM Products). Its RAAM Products and related services are principally used in the health care industry administered through doctors and clinics. It has developed and begun to distribute additional products that incorporate its proprietary ingredients for products to be used in topical aesthetic applications and is actively exploring further development of additional products to be used in other topical aesthetic applications.
Employees
20
Date Price Change Volume
21/08/26 USD 1.571 +10.63% 482
20/08/26 USD 1.420 +6.45% 752
19/08/26 USD 1.334 -13.94% 4,333
18/08/26 USD 1.550 +10.71% 416
17/08/26 USD 1.400 -.--% 442
  1. Stock Market
  2. Stocks
  3. ZEOX Stock